Truffle Capital, an investor in Splicos, is a European private equity firm originally set up for investments in spin-offs from companies active in the IT, Energy, and Life Sciences sectors.
- Splicos SAS is a Montpellier based academic spin off from two CNRS institutes: IGMM (Molecular Genetics Institute of Montpellier) and CRBM (Macromolecular Biochemistry Research Center of Montpellier), which have developed breakthrough technologies in the fields of alternative splicing and metastatic migration. Splicos is negotiating with CNRS the worldwide exclusive rights to exploit those discoveries which will lead to new therapeutic solutions in virology, especially AIDS, oncology and genetic diseases. The company’s mission is to generate drug candidates to be developed and marketed through strategic alliances concluded at an early stage with pharmaceutical or biotechnological players.
- After an initial Truffle seed funding of €300,000, the company is presently securing further additional resources from Truffle and grant agencies.
Truffle Capital board member: Dr. Philippe Pouletty